26364-65-8Relevant articles and documents
MLKL INHIBITORS
-
Paragraph 0997-0999, (2018/09/26)
Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.
An antibiotic anticancer active compound
-
Paragraph 0042-0046, (2017/04/28)
The invention discloses an anti-bacterial and anti-cancer active compound. The anti-bacterial and anti-cancer active compound or an addition product thereof is shown in the specification, wherein substituent groups of R1, R2, R3 and R4 are selected from a hydroxyl, an amino group, a nitryl, a halogen atom, a hydrogen atom, a C1-6 alkyl, a C2-6 alkenyl, a C6-10 aryl, a C1-6 alkyl acylamino group or a C1-6 alkoxy carbonyl. A novel compound is prepared by a hydrochloride salt, has an anti-bacterial effect and significant anti-cancer activity, and has good clinical application values.
PROCESS FOR PREPARING CYANIMINO-1,3-THIAZOLIDINES
-
Page/Page column 5, (2009/04/25)
The present invention relates to a process for preparing cyanimino-1,3-thiazolidines, which are important building blocks for the preparation of crop protection active ingredients and pharmaceuticals, by the following scheme: where A is an alkali metal an